Kim K S, Denton M D, Chandraker A, Knoflach A, Milord R, Waaga A M, Turka L A, Russell M E, Peach R, Sayegh M H
Laboratory of Immunogenetics, Renal Division, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02115, USA.
Am J Pathol. 2001 Mar;158(3):977-86. doi: 10.1016/S0002-9440(10)64044-8.
Provision of adequate T cell costimulation is critical for the development of acute and chronic allograft rejection. We have previously reported that early blockade of CD28-B7 T cell costimulation prevents the development of graft arteriosclerosis, in the LEW into F344 rat cardiac transplant model. In this study, we used the same model to examine the requirement for CD28-B7-mediated T cell costimulation in the progression of established chronic rejection and examined the individual roles of B7-1 (CD80) and B7-2 (CD86) costimulatory molecules. Late blockade of CD28-B7 T cell costimulation by the fusion protein CTLA4Ig, which binds both CD80 and CD86, attenuated the development of transplant arteriosclerosis, mononuclear cell infiltration, and parenchymal fibrosis in this model. Selective blockade of CD80 using the mutant fusion protein Y100F was as effective as CTLA4Ig in this regard. In contrast to CTLA4Ig, blockade of CD80 alone by Y100F was ineffective at preventing early graft loss and prolonging graft survival when given early after transplantation. This study is the first to demonstrate that late blockade of CD28-B7 T cell costimulation interrupts chronic cardiac allograft rejection, and it indicates the importance of continued T cell activation in this process. This study further defines functional differences between CD80 and CD86 costimulatory molecules in vivo.
提供充足的T细胞共刺激对于急性和慢性移植排斥反应的发生至关重要。我们之前报道过,在LEW到F344大鼠心脏移植模型中,早期阻断CD28 - B7 T细胞共刺激可预防移植动脉硬化的发生。在本研究中,我们使用相同模型来检测在已建立的慢性排斥反应进展过程中CD28 - B7介导的T细胞共刺激的必要性,并研究共刺激分子B7 - 1(CD80)和B7 - 2(CD86)各自的作用。通过结合CD80和CD86的融合蛋白CTLA4Ig对CD28 - B7 T细胞共刺激进行晚期阻断,可减轻该模型中移植动脉硬化、单核细胞浸润及实质纤维化的发展。在这方面,使用突变融合蛋白Y100F选择性阻断CD80与CTLA4Ig效果相同。与CTLA4Ig不同,移植后早期给予Y100F单独阻断CD80在预防早期移植物丢失和延长移植物存活方面无效。本研究首次证明CD28 - B7 T细胞共刺激的晚期阻断可中断慢性心脏移植排斥反应,并表明在此过程中持续的T细胞活化的重要性。本研究进一步明确了体内CD80和CD86共刺激分子之间的功能差异。